Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37


CD81 is a novel immunotherapeutic target for B cell lymphoma.

Vences-Catalán F, Kuo CC, Rajapaksa R, Duault C, Andor N, Czerwinski DK, Levy R, Levy S.

J Exp Med. 2019 May 23. pii: jem.20190186. doi: 10.1084/jem.20190186. [Epub ahead of print]


Single-cell RNA-Seq of follicular lymphoma reveals malignant B-cell types and coexpression of T-cell immune checkpoints.

Andor N, Simonds EF, Czerwinski DK, Chen J, Grimes SM, Wood-Bouwens C, Zheng GXY, Kubit MA, Greer S, Weiss WA, Levy R, Ji HP.

Blood. 2019 Mar 7;133(10):1119-1129. doi: 10.1182/blood-2018-08-862292. Epub 2018 Dec 27.


B-cell lymphomas present immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Chen B, Sworder B, Shree T, Liu CL, Zhang L, Czerwinski DK, Davis MM, Levy R, Elias JE, Alizadeh AA.

Blood. 2019 Feb 21;133(8):878-881. doi: 10.1182/blood-2018-06-845156. Epub 2018 Dec 13. No abstract available.


In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma.

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK, Long SR, Hoppe RT, Janssen R, Candia AF, Coffman RL, Levy R.

Cancer Discov. 2018 Oct;8(10):1258-1269. doi: 10.1158/2159-8290.CD-18-0743. Epub 2018 Aug 28.


Imaging activated T cells predicts response to cancer vaccines.

Alam IS, Mayer AT, Sagiv-Barfi I, Wang K, Vermesh O, Czerwinski DK, Johnson EM, James ML, Levy R, Gambhir SS.

J Clin Invest. 2018 Jun 1;128(6):2569-2580. doi: 10.1172/JCI98509. Epub 2018 May 14.


T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins.

Olsson N, Schultz LM, Zhang L, Khodadoust MS, Narayan R, Czerwinski DK, Levy R, Elias JE.

Proteomics. 2018 Jun;18(12):e1700410. doi: 10.1002/pmic.201700410. Epub 2018 Apr 18.


Eradication of spontaneous malignancy by local immunotherapy.

Sagiv-Barfi I, Czerwinski DK, Levy S, Alam IS, Mayer AT, Gambhir SS, Levy R.

Sci Transl Med. 2018 Jan 31;10(426). pii: eaan4488. doi: 10.1126/scitranslmed.aan4488.


Antigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens.

Khodadoust MS, Olsson N, Wagar LE, Haabeth OA, Chen B, Swaminathan K, Rawson K, Liu CL, Steiner D, Lund P, Rao S, Zhang L, Marceau C, Stehr H, Newman AM, Czerwinski DK, Carlton VE, Moorhead M, Faham M, Kohrt HE, Carette J, Green MR, Davis MM, Levy R, Elias JE, Alizadeh AA.

Nature. 2017 Mar 30;543(7647):723-727. doi: 10.1038/nature21433. Epub 2017 Mar 22.


Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.


Holbrook Kohrt: In Memoriam (1977-2016).

Houot R, Pachynski R, Czerwinski DK, Goldstein MJ, Sagiv-Barfi I, Brody J, Müller AM, Marabelle A.

Clin Cancer Res. 2016 Jul 15;22(14):3695-6. doi: 10.1158/1078-0432.CCR-16-1181. No abstract available.


Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R.

Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72. doi: 10.1073/pnas.1500712112. Epub 2015 Feb 17.


Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.

Sagiv-Barfi I, Kohrt HE, Burckhardt L, Czerwinski DK, Levy R.

Blood. 2015 Mar 26;125(13):2079-86. doi: 10.1182/blood-2014-08-593137. Epub 2015 Feb 6.


High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells.

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R.

Blood. 2013 Feb 21;121(8):1367-76. doi: 10.1182/blood-2012-04-421826. Epub 2013 Jan 7.


Cancer vaccines and T cell therapy.

Rezvani K, Brody JD, Kohrt HE, Logan AC, Advani R, Czerwinski DK, Weng WK, Negrin RS, Carlton V, Faham M, Levy R, Barrett J.

Biol Blood Marrow Transplant. 2013 Jan;19(1 Suppl):S97-S101. doi: 10.1016/j.bbmt.2012.09.020. Epub 2012 Oct 3. Review. No abstract available.


CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Anderson MW, Zhao S, Freud AG, Czerwinski DK, Kohrt H, Alizadeh AA, Houot R, Azambuja D, Biasoli I, Morais JC, Spector N, Molina-Kirsch HF, Warnke RA, Levy R, Natkunam Y.

Am J Pathol. 2012 Sep;181(3):795-803. doi: 10.1016/j.ajpath.2012.05.015.


In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study.

Kim YH, Gratzinger D, Harrison C, Brody JD, Czerwinski DK, Ai WZ, Morales A, Abdulla F, Xing L, Navi D, Tibshirani RJ, Advani RH, Lingala B, Shah S, Hoppe RT, Levy R.

Blood. 2012 Jan 12;119(2):355-63. doi: 10.1182/blood-2011-05-355222. Epub 2011 Nov 1.


A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.

Goldstein MJ, Varghese B, Brody JD, Rajapaksa R, Kohrt H, Czerwinski DK, Levy S, Levy R.

Blood. 2011 Jan 6;117(1):118-27. doi: 10.1182/blood-2010-06-288456. Epub 2010 Sep 27.


In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, Kim YH, Hoppe RT, Knox SJ, Shin LK, Wapnir I, Tibshirani RJ, Levy R.

J Clin Oncol. 2010 Oct 1;28(28):4324-32. doi: 10.1200/JCO.2010.28.9793. Epub 2010 Aug 9.


B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression.

Irish JM, Myklebust JH, Alizadeh AA, Houot R, Sharman JP, Czerwinski DK, Nolan GP, Levy R.

Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):12747-54. doi: 10.1073/pnas.1002057107. Epub 2010 Jun 11.


Generation of CD8+ T cell-mediated immunity against idiotype-negative lymphoma escapees.

Varghese B, Widman A, Do J, Taidi B, Czerwinski DK, Timmerman J, Levy S, Levy R.

Blood. 2009 Nov 12;114(20):4477-85. doi: 10.1182/blood-2009-05-223263. Epub 2009 Sep 17.


Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma.

Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R.

Leuk Lymphoma. 2009 Jan;50(1):37-46. doi: 10.1080/10428190802563355.


Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.

Brody JD, Goldstein MJ, Czerwinski DK, Levy R.

Blood. 2009 Jan 1;113(1):85-94. doi: 10.1182/blood-2008-05-155457. Epub 2008 Sep 23.


Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.

Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R.

J Immunol. 2007 Aug 15;179(4):2493-500.


Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry.

Irish JM, Czerwinski DK, Nolan GP, Levy R.

J Immunol. 2006 Aug 1;177(3):1581-9.


Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.

Lossos IS, Czerwinski DK, Alizadeh AA, Wechser MA, Tibshirani R, Botstein D, Levy R.

N Engl J Med. 2004 Apr 29;350(18):1828-37.


Optimization of quantitative real-time RT-PCR parameters for the study of lymphoid malignancies.

Lossos IS, Czerwinski DK, Wechser MA, Levy R.

Leukemia. 2003 Apr;17(4):789-95.


Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.

Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R.

Cancer Res. 2002 Oct 15;62(20):5845-52.


Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients.

Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A, Liles TM, Engleman EG, Levy R.

Blood. 2002 Mar 1;99(5):1517-26.


Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry.

Maecker HT, Auffermann-Gretzinger S, Nomura LE, Liso A, Czerwinski DK, Levy R.

Clin Cancer Res. 2001 Mar;7(3 Suppl):902s-908s.


Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Maloney DG, Liles TM, Czerwinski DK, Waldichuk C, Rosenberg J, Grillo-Lopez A, Levy R.

Blood. 1994 Oct 15;84(8):2457-66.


Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors.

Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R.

N Engl J Med. 1992 Oct 22;327(17):1209-15.


B-cell activation and immunoregulation in end-stage renal disease patients receiving hemodialysis.

Raskova J, Ghobrial I, Czerwinski DK, Shea SM, Eisinger RP, Raska K Jr.

Arch Intern Med. 1987 Jan;147(1):89-93.


Cellular immunity and lymphocyte populations in developing uremia in the rat.

Raskova J, Czerwinski DK, Shea SM, Raska K Jr.

J Exp Pathol. 1986 Summer;2(4):229-45.


Supplemental Content

Loading ...
Support Center